Center for Cancer Immune Therapy (CCIT)

Medicine & Life Sciences

1. T-Lymphocytes 100%
2. Melanoma 82%
3. Neoplasms 64%
4. Tumor-Infiltrating Lymphocytes 46%
5. Immunotherapy 41%
6. Vaccination 35%
7. Dendritic Cells 34%
8. Peptides 29%
9. Ipilimumab 22%
10. Indoleamine-Pyrrole 2,3,-Dioxygenase 21%
11. Cell- and Tissue-Based Therapy 21%
12. Therapeutics 21%
13. Neoplasm Antigens 20%
14. Tumor Microenvironment 20%
15. Vaccines 20%
16. Epitopes 19%
17. Antigens 19%
18. Survival 15%
19. Nivolumab 12%
20. Cancer Vaccines 12%
21. Subunit Vaccines 11%
22. Regulatory T-Lymphocytes 11%
23. Interleukin-2 11%
24. Adoptive Transfer 10%
25. Arginase 10%
26. Calreticulin 10%
27. Immune System 9%
28. Immunity 9%
29. Ligands 9%
30. Survivin 9%
31. Ovarian Neoplasms 8%
32. Interferons 8%
33. HLA-A2 Antigen 8%
34. Cytokines 7%
35. Renal Cell Carcinoma 7%
36. Mutation 7%
37. Breast Neoplasms 7%
38. Tissue Donors 6%
39. pembrolizumab 6%
40. Histocompatibility Antigens Class I 6%
41. Proteins 6%
42. Prostatic Neoplasms 6%
43. Natural Killer Cells 6%
44. Chimeric Antigen Receptors 6%
45. Biomarkers 6%
46. Castration 6%
47. Phenotype 6%
48. HLA Antigens 6%
49. Progression-Free Survival 6%
50. Cutaneous T-Cell Lymphoma 6%
51. T-Cell Antigen Receptor 6%
52. Antibodies 6%
53. Immunosuppressive Agents 6%
54. Collagen 5%
55. In Vitro Techniques 5%
56. T-Lymphocyte Epitopes 5%
57. Monocytes 5%
58. Clinical Trials, Phase I 5%
59. Pancreatic Neoplasms 5%
60. Cytotoxic T-Lymphocytes 5%
61. Clinical Trials 5%
62. Hematologic Neoplasms 5%
63. Polycythemia Vera 5%
64. Population 5%
65. Major Histocompatibility Complex 5%
66. Multiple Myeloma 5%